ConductScience.org, home

Paper29370992

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.

D'Angelo SP and 10 others. Lancet Oncol, 2018. Cited by 630 papers, by iCite.

Cite this record

ConductScience Library. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Papers, record 29370992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29370992

Download JSON
Disease
sarcoma179 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
PubMed
Journal
Lancet Oncol
PubMed
Year
2018
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
630
iCite
Relative citation ratio, by iCite
22
iCite
Revised in PubMed
2026-03-01
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1D'Angelo SPSandra P
2Mahoney MRMichelle R
3Van Tine BABrian A
4Atkins JJames
5Milhem MMMohammed M
6Jahagirdar BNBalkrishna N
7Antonescu CRCristina R
8Horvath EElise
9Tap WDWilliam D
10Schwartz GKGary K
11Streicher HHoward

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, ImmunologicalMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
IpilimumabMajor topic
NivolumabMajor topic
SarcomaMajor topic
Soft Tissue NeoplasmsMajor topic
Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Time Factors
Treatment Outcome
United States
Young Adult

Source PubMed

Download CSV of topics

Grants14

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
U10 CA180821NCI NIH HHSUnited StatesU10CA180821PubMed and NIHNIH RePORTER
U10 CA041287NCI NIH HHSUnited StatesU10CA041287PubMed and NIHNIH RePORTER
U10 CA077651NCI NIH HHSUnited StatesU10CA077651PubMed and NIHNIH RePORTER
U10 CA180882NCI NIH HHSUnited StatesU10CA180882PubMed and NIHNIH RePORTER
U10 CA180833NCI NIH HHSUnited StatesU10CA180833PubMed and NIHNIH RePORTER
U10 CA047642NCI NIH HHSUnited StatesU10CA047642PubMed and NIHNIH RePORTER
U10 CA045808NCI NIH HHSUnited StatesU10CA045808PubMed and NIHNIH RePORTER
U10 CA007968NCI NIH HHSUnited StatesU10CA007968PubMed and NIHNIH RePORTER
U10 CA180836NCI NIH HHSUnited StatesU10CA180836PubMed and NIHNIH RePORTER
UG1 CA189858NCI NIH HHSUnited StatesUG1CA189858PubMed and NIHNIH RePORTER
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER
U10 CA077440NCI NIH HHSUnited StatesU10CA077440PubMed and NIHNIH RePORTER
U10 CA180791NCI NIH HHSUnited StatesU10CA180791PubMed and NIHNIH RePORTER
P30CA086862NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02500797Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by SurgeryDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in29370991A start towards immunotherapy in sarcomas?https://conductscience.org/library/papers/29370991

Source PubMed

Download CSV of comments and corrections

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126874885Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.Lancet2016https://conductscience.org/library/papers/26874885PubMed
223724867Nivolumab plus ipilimumab in advanced melanoma.N Engl J Med2013https://conductscience.org/library/papers/23724867PubMed
320004617Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.Lancet Oncol2010https://conductscience.org/library/papers/20004617PubMed
420160101PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.Proc Natl Acad Sci U S A2010https://conductscience.org/library/papers/20160101PubMed
526952546Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Lancet2016https://conductscience.org/library/papers/26952546PubMed
622595799Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet2012https://conductscience.org/library/papers/22595799PubMed
725428505PD-1 blockade induces responses by inhibiting adaptive immune resistance.Nature2014https://conductscience.org/library/papers/25428505PubMed
825765070Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Science2015https://conductscience.org/library/papers/25765070PubMed
927592805Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.Lancet Oncol2016https://conductscience.org/library/papers/27592805PubMed
102702835Optimal two-stage designs for phase II clinical trials.Control Clin Trials1989https://conductscience.org/library/papers/2702835PubMed
1125891304Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N Engl J Med2015https://conductscience.org/library/papers/25891304PubMed
1223554566A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.Sarcoma2013https://conductscience.org/library/papers/23554566PubMed
1328440953Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.Cancer2017https://conductscience.org/library/papers/28440953PubMed
1427291997Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.Lancet2016https://conductscience.org/library/papers/27291997PubMed
1522437870The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer2012https://conductscience.org/library/papers/22437870PubMed
1620525992Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med2010https://conductscience.org/library/papers/20525992PubMed
1726371143Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.J Clin Oncol2016https://conductscience.org/library/papers/26371143PubMed
1826712084Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.Lancet2016https://conductscience.org/library/papers/26712084PubMed
1925795410Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.Lancet Oncol2015https://conductscience.org/library/papers/25795410PubMed
201100130Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.Biometrics1975https://conductscience.org/library/papers/1100130PubMed

See all 25 referencesDownload CSV of references

Cited by480

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 630 citations.

PMIDTitleJournalYearIn PapersSource
42958422Tazemetostat combined PD-1 inhibitor achieving prolonged survival in primary proximal epithelioid sarcoma: a case report and review of the literature.J Med Case Rep2026https://conductscience.org/library/papers/42958422PubMed
42939993CD47-SIRPα as a Therapeutic Target in Sarcoma: A Systematic Review of Expression, Preclinical, and Clinical Evidence.Biomedicines2026https://conductscience.org/library/papers/42939993PubMed
42855246Pembrolizumab plus lenvatinib in the treatment of unresectable cutaneous angiosarcoma: a study protocol of multicentre, open-label phase II study (NCCH2213, PLAS).BMJ Open2026https://conductscience.org/library/papers/42855246PubMed
42835191Advances in uterine sarcoma management: A mini-review of clinical practice and molecular insights.Gynecol Oncol Rep2026https://conductscience.org/library/papers/42835191PubMed
42826198An immunocompetent, multifluorescent resource for real-time analysis of osteosarcoma progression, metastasis, and response to therapy.Sci Adv2026https://conductscience.org/library/papers/42826198PubMed
42783458Pleomorphism in Soft Tissue Sarcomas: Molecular Characteristics and Clinical Features.Med Sci (Basel)2026https://conductscience.org/library/papers/42783458PubMed
42769412Rule-derived preoperative inflammatory-lymphocyte recovery phenotype and pathological response in resected osteosarcoma: a retrospective cohort study.Front Immunol2026https://conductscience.org/library/papers/42769412PubMed
42707561Dynamic immune state transitions and metastatic niche remodelling drive osteosarcoma evolution as a barrier-restricted immune-cold ecosystem.Front Immunol2026https://conductscience.org/library/papers/42707561PubMed
42675610Real-world experience with ipilimumab in combination with nivolumab in advanced sarcoma: a retrospective analysis including ultra-rare sarcomas.Oncologist2026https://conductscience.org/library/papers/42675610PubMed
42650028Epithelioid Sarcoma: A Review and Update.Cancers (Basel)2026https://conductscience.org/library/papers/42650028PubMed
42569618Complete Response to Pembrolizumab in Radiation-Induced Undifferentiated Pleomorphic Sarcoma of the Face: A Case Report and Review of the Literature.Case Rep Oncol2026https://conductscience.org/library/papers/42569618PubMed
42558163Osteosarcoma as a communication-driven disease: redefining tumor-bone signaling networks as therapeutic targets.Front Oncol2026https://conductscience.org/library/papers/42558163PubMed
42556071Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances.Cancer Treat Rev2026https://conductscience.org/library/papers/42556071PubMed
42529121Recurrent retroperitoneal sarcoma: beyond resectability toward a biology-based therapeutic framework.Oncol Rev2026https://conductscience.org/library/papers/42529121PubMed
42527032Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma.J Immunother Cancer2026https://conductscience.org/library/papers/42527032PubMed
42525308Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives.Curr Treat Options Oncol2026https://conductscience.org/library/papers/42525308PubMed
42512423Pharmacologic Resistance in Soft Tissue Sarcomas: Mechanisms, Biomarkers, and Translational Therapeutic Strategies.Cancers (Basel)2026https://conductscience.org/library/papers/42512423PubMed
42505406Immunotherapy in Soft Tissue Sarcomas-An Ongoing Quest.Cells2026https://conductscience.org/library/papers/42505406PubMed
42494596Promising effects of high-intensity focused ultrasound combined with eribulin and sintilimab in a patient with advanced leiomyosarcoma: a case report and literature review.Front Oncol2026https://conductscience.org/library/papers/42494596PubMed
42352340Understanding and Overcoming Osteosarcoma Heterogeneity.Biomolecules2026https://conductscience.org/library/papers/42352340PubMed

See all 480 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ASPSCR179058PubTator's text mininghttps://conductscience.org/library/genes/79058NCBI Gene
ATRX546PubTator's text mininghttps://conductscience.org/library/genes/546NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
GPT2875PubTator's text mininghttps://conductscience.org/library/genes/2875NCBI Gene
NOS14842PubTator's text mininghttps://conductscience.org/library/genes/4842NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
IPILIMUMABCHEMBL1789844Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1789844ChEMBL
NIVOLUMABCHEMBL2108738Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2108738ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29370992

GET https://conductscience.org/api/papers/v1/29370992/references?page=2